NCT06099366
招募中
2 期
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in
Hee Young Ju9 个研究点 分布在 1 个国家目标入组 116 人2024年3月5日
相关药物induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal MethotrexateConsolidation: Vincristine, Mecaptopurine, Intrathecal MethotrexateConsolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal MethotrexateInterim Maintenance(IM): Vincristine, Methotrexate, Intrathecal MethotrexateInterim Maintenance(IM): Vincristine, Methotrexate, Mercaptopurine, Intrathecal MethotrexateDelayed Intesification(DI): Vincristine, Mercaptopurine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal MethotrexateDelayed Intesification(DI): Vincristine, L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Dexamethasone, Intrathecal MethotrexateMaintenance: Vincristine, Mercaptopurine, Methotrexate, Dexamethasone, Intrathecal Methotrexate
概览
- 阶段
- 2 期
- 干预措施
- 未指定
- 疾病 / 适应症
- Lymphoblastic Leukemia in Children
- 发起方
- Hee Young Ju
- 入组人数
- 116
- 试验地点
- 9
- 主要终点
- 5-year event free survival rate
- 状态
- 招募中
- 最后更新
- 10个月前
概览
简要总结
Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for high risk acute lymphoblastic leukemia in children and adolescents.
研究者
Hee Young Ju
Clinical Professor
Samsung Medical Center
入排标准
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
5-year event free survival rate
时间窗: Up to 5-years
次要结局
- Confirmation of the therapeutic effect of the initial treatment response(Up to 5-years)
- Disease prognosis-related factor(Up to 5-years)
研究点 (9)
Loading locations...
相似试验
招募中
不适用
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children.NeoplasmsKCT0009042Samsung Medical Center116
已完成
2 期
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaAdult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaNCT03226418University of Nebraska75
进行中（未招募）
3 期
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaAcute Lymphoblastic LeukemiaAdult B Lymphoblastic LymphomaAnn Arbor Stage I B Lymphoblastic LymphomaAnn Arbor Stage II B Lymphoblastic LymphomaChildhood B Acute Lymphoblastic LeukemiaChildhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Childhood B Lymphoblastic LymphomaDown SyndromeHypodiploid B Acute Lymphoblastic LeukemiaPhiladelphia Chromosome PositiveNCT01190930Children's Oncology Group9,350
已完成
4 期
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)Acute Promyelocytic LeukemiaNCT00408278PETHEMA Foundation300
已完成
3 期
Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)Acute Myeloid LeukemiaNCT00266136University Hospital Muenster3,500